109 DIVISION OF HEM/ONC: ONCOLOGY BOARD REVIEW CONFERENCE " Resistance to Endocrine Therapy in ER+ Breast Cancer: Insights from Bedside to Bench Studies " (012722)_NOT ACCREDITED

Dallas, TX US
January 27, 2022
Course summary
Available credit: 
  • 1.00 AMA
  • 1.00 Attendance
Course opens: 
01/27/2022
Course expires: 
01/27/2022
Event starts: 
01/27/2022 - 7:30am CST
Event ends: 
01/27/2022 - 8:30am CST
Cost:
$0.00
UT Southwestern Medical Center
5323 Harry Hines Blvd.
Dallas, TX 75390
United States
Course Director(s)

Amy Jones, M.D.

has no relevant financial relationships to disclose at this time.
Speaker(s)

Carlos Arteaga, Professor & Director, Simmons Comprehensive Cancer Center, Internal Medicine, Office of the Dean - Southwestern Medical School

has a financial relationship (Professional Services) with TAIHO Oncology;.
has a financial relationship (Professional Services) with OrigiMed;.
has a financial relationship (Professional Services) with Athenex;.
has a financial relationship (Stock Options) with Provista;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Grant Or Contract) with Lilly;.
has a financial relationship (Professional Services) with Lilly;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with ARVINAS;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Professional Services) with Immunomedics;.
has a financial relationship (Professional Services) with Susan G. Komen;.

Amy Jones, M.D.

has no relevant financial relationships to disclose at this time.

Available Credit

  • 1.00 AMA
  • 1.00 Attendance

Price

Cost:
$0.00
Please login or create an account to take this course.